Drug
Sorted by
24h volume
Hide near-certain
Polymarket
Fetching top markets…
Market
Category
Probability
24h Vol
Volume
Ends
FDA approves Retatrutide this year?
Science
FDA
98%
No
$101
$577.7K
Dec 31, 2026
FDA approves Daraxonrasib this year?
Science
drug
61%
No
—
$1.4K
Dec 31, 2026
FDA approves Viatris' low-dose estrogen weekly patch?
Tech
Medicine
69%
Yes
—
$4.6K
Jul 30, 2026
3
markets